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Abstract
Purpose Individualized patient care may help reduce the
incidence of adverse drug events in systemic cancer therapy.
This study was conducted to explore the feasibility and
potential of additional pharmaceutical care for breast and
ovarian cancer patients.
Methods The study was designed as a prospective, multi-
centered cohort study with a control group. Ninety-eight
breast or ovarian cancer patients were recruited from outpa-
tient oncology clinics and primary care oncologists: initially
into the control group receiving standard care and after
implementation of pharmaceutical care into the intervention
group consisting of additional patient counseling on the
management of treatment-associated adverse events and
optimization of supportive medication. Primary outcome
was the complete response to the antiemetic prophylaxis.
Secondary endpoints were the severity of nausea, frequency of
emesis, health-related quality of life, and patient satisfaction
with information on cancer treatment education.
Results Forty-eight patients were included in the control
group and 50 in the intervention group. Of the patients,
35.4% in the control group and 76.0% in the intervention
group (p<0.001) had a complete response to the antiemetic
prophylaxis. The severity of acute and delayed nausea was
not reduced. The global health scale and two symptom
scales (nausea and vomiting, appetite loss) of the EORTC
QLQ-C30 questionnaire were positively affected by phar-
maceutical care. Patient satisfaction with information was
significantly higher in the intervention group.
Conclusions Patients with breast and ovarian cancer seem to
benefit from pharmaceutical care, as suggested by improved
patient-reported outcomes such as emetic episodes, quality of
life, and patient satisfaction after implementation.
Keywords Breast cancer . Patient-reported outcomes .
Pharmaceutical care . Quality of life . Toxicity . Supportive
care
Introduction
Therapeutic strategies for cancer patients are highly
individualized and include a variety of drugs with different
pharmacological mechanisms and targets. As anticancer
therapy is often associated with severe adverse drug events,
there is an increasing demand for effective supportive care
strategies preventing or ameliorating drug-induced toxicity.
In the last decade, several evidence-based clinical practice
guidelines have been developed for supportive care. Still,
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adverse drug events range high among the most feared
consequences associated with antineoplastic therapy [1].
Chemotherapy-induced nausea and vomiting is considered
to be substantially distressing for the patients and should be
addressed by oncology care services [2]. However, Mertens et
al. showed that physicians do not always adhere adequately to
antiemetic prescribing guidelines, indicating that the sole dis-
tribution of guidelines does not lead to a better control of
nausea and vomiting. The situation improved after nurse
practitioner antiemetic prescribing was introduced [3].
It is widely accepted that multidisciplinary care models
have a high potential to enhance patient safety [4]. Considering
the fact that patients with solid tumors are mainly treated in
outpatient settings, structured patient counseling on their indi-
vidual chemotherapy including medication reconciliation may
be of particular benefit to patients experiencing transitions in
care [5]. Pharmaceutical care is a concept, which may
contribute to this approach. It is defined as the responsible
provision of drug therapy for the purpose of achieving definite
outcomes that improve a patient’s quality of life [6]. The
addition of a pharmacist to the health care team may ensure
appropriate medication use and maximize adherence, as
recently stated in a NCCN Task Force Report [7]. As
antineoplastic drug therapy follows established protocols,
pharmaceutical care models in oncology aim at minimizing
treatment-related toxicity and, therefore, focus on optimizing
supportive care strategies [8]. Moreover, they include individ-
ualized patient information on adverse events as this is of great
importance for many patients [9]. Different coping strategies
are associated with different needs regarding amount and depth
of information [10]. Therefore, patient satisfaction and the
capability to initiate self-care behavior depend on the quality
of individually tailored information.
New treatment strategies and care models are increasing-
ly evaluated by means of patient-reported outcomes (PROs)
[11]. In oncology, self-reporting of toxicity symptoms has
successfully been established, which may provide some
advantages over reporting by clinicians [12]. The aim of
this study was to explore the feasibility and potential of
pharmaceutical care for breast and ovarian cancer patients
treated in outpatient settings in Germany by measuring
PROs. The pharmaceutical care model included the use of
supportive medication according to evidence-based treatment




Six academic- and community-based outpatient clinics as
well as two primary care oncologists in West and North
Germany participated in the study. Patients with a diag-
nosis of breast or ovarian cancer receiving their first
chemotherapy were consecutively recruited in each cen-
ter. All standard adjuvant and neoadjuvant chemothera-
py regimens for the treatment of breast and ovarian
cancer were allowed. Patients had to be at least 18 years
of age, give their written informed consent, and be able
to speak, read, and write German. Patients were exclud-
ed from the study if they had diseases or mental states
which impeded that the patient completely understood
the provided information on the study or if the patient
had an impaired capability of reading and completing
questionnaires self-administered. Written informed consent
was obtained from all participating patients prior to any
study-related procedures.
Study design
The study was conducted as a prospective, multicentered
cohort study with a control group. At each center, patients
were first recruited into the control group and then into the
intervention group. This nonrandomized design was chosen
to avoid contamination bias caused by inevitable interaction
between patients of the two groups and learning effects
among the health care professionals. The study was ap-
proved by the ethics committee of the Medical Association
of North Rhine, Germany and registered at the German
Clinical Trials Register (DRKS00000765).
Pharmaceutical care intervention
Patients in the control group received their treatment
according to standard practice in Germany. They did not
have regularly scheduled appointments with a pharmacist
and were not exposed to pharmaceutical care.
Patients in the intervention group had regular appointments
with the pharmacist providing pharmaceutical care. The
medication was systematically documented in order to check
for potential drug–drug interactions. The intervention con-
sisted of two major components: the application of an algo-
rithm for evidence-based antiemetic prophylaxis and treatment
and medication counseling of the patients before and during
their courses of chemotherapy.
The algorithm was developed by multidisciplinary con-
sensus. The pharmacist drafted a tentative algorithm based
on current evidence-based guidelines which served as a
basis for discussion with the participating oncologists.
During this discussion, the algorithm was modified until a
consensus was reached. After implementation, the physi-
cians chose the antiemetic prophylaxis for the patients of
the intervention group according to the algorithm. Each
prescription was checked by the pharmacist for adherence
to the algorithm. Modifications were proposed if required.
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However, each physician had the final decision responsibil-
ity on whether the prescription was modified or not.
In addition, the patients were counseled regarding the
optimal use of the supportive medication. Patients received
general oral and written information about chemotherapy,
potential adverse effects, and preventative strategies. In
particular, patients were informed by the pharmacist about
the antiemetic treatment, the importance of consequent pro-
phylactic drug intake, the use of rescue medication, the
mode of administration, and the correct dosing.
Endpoints
“Complete response (CR) emesis,” defined as no emetic
episode on the 5 days following chemotherapy, was the
primary endpoint of the study. It was measured using a
patient diary developed by Freidank [13], which covered
both the acute and delayed phases of nausea and vomiting.
Patients were asked to report the emetic episodes and clas-
sify the experienced nausea from degree 0 to 4 (“no nausea”
to “severe nausea, which makes everyday life impossible”).
Nausea and vomiting were documented after each cycle of
chemotherapy in order to allow longitudinal evaluation of
the data.
The severity of nausea and the frequency of vomiting
were measured as secondary endpoints using the sum scores
of the reported degrees of nausea and the number of emetic
events, respectively, divided by the number of documented
cycles in the acute and delayed phases.
Another secondary endpoint was health-related quality of
life. It was measured with the validated German version of
the cancer-specific EORTC QLQ-C30 (version 3.0) ques-
tionnaire [14] before the beginning, in the middle (after the
second cycle for patients receiving four cycles of chemo-
therapy or after the third cycle for patients receiving six
cycles of chemotherapy), and at the end of treatment (after
the fourth or sixth cycle, respectively). For the second and
third measurement, patients were asked to complete the
QLQ-C30 questionnaire 1 week after chemotherapy admin-
istration. The scale values of the questionnaire were calcu-
lated according to the scoring manual provided by the
EORTC [15]. Then, the absolute changes in the different
scales over the treatment period compared to baseline were
calculated, after reassuring that there were no differences
between the groups at baseline.
Patient satisfaction with information on cancer treatment
was measured as a secondary endpoint using the Canadian
PS-CaTE questionnaire which had been translated into Ger-
man and tested for its psychometric properties before [16].
Patients were asked to fill in the questionnaire after the last
chemotherapy cycle. The questionnaire can be divided into
four subscales and one global scale. The scale values were
calculated as described by Liekweg et al. [16].
Sample size calculation
The sample size calculation was performed by power
simulation for the primary endpoint because, so far, no
algorithms or programs are available to calculate the
sample size for nonparametric analysis of variance. For
this purpose, with different combinations of the group
size (n), the prevalence in the control group (p), and the
expected difference (Δ), 10,000 simulations were per-
formed at a time and the power was calculated for a
type 1 error α05%. The simulations were performed by
S-Plus® 2000. With a sample size of n050 per group
and a prevalence of CR emesis of 40% to 60% in the
control group, an improvement of Δ015% in the inter-
vention group can be detected with a power (1−β) of
more than 99%.
Statistical methods
SPSS version 12.0 and SAS version 9.1 were used for
the statistical analyses. In order to evaluate the primary
endpoint “CR emesis,” the two groups were compared
using the Kaplan–Meier analysis and the log-rank test
as well as Fisher’s exact test for individual cycles. For
the other endpoints, Mann–Whitney U test was used to
compare both groups. As this was a longitudinal analy-
sis with multiple measurements over time, a nonpara-
metric factorial analysis for repeated measurements was
performed to compare endpoints between groups over
time, using treatment group as whole plot factor and
time as split plot factor [17]. This analysis is based on
ranks and assumes that measurements within one group
at the same time point follow the same unspecified
distribution. Measurements within one person over time
may be correlated; however, no correlation structure was
specified. p values <0.05 were considered statistically
significant.
Moreover, a logistic regression was performed using
aprepitant treatment and pharmaceutical care as indepen-
dent variables in order to distinguish the influence of
both interventions on CR emesis. The results are dis-
played with odds ratios, their 95% confidence intervals,
and the p value.
Results
Patient population
Forty-eight patients of the control group and 50 patients of
the intervention group were included in the analysis. The
demographic characteristics of the patient population at
baseline are presented in Table 1.
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Complete response emesis
Pharmaceutical care led to a significant improvement of the
primary endpoint “CR emesis” during the first four cycles of
chemotherapy (Table 2). The nonsignificant results in cycles
5 and 6 are probably due to the small number of patients
receiving these cycles. The longitudinal nonparametric anal-
ysis of variance according to Brunner confirmed the cycle-
wise results with a p value <0.001. The Kaplan–Meier
curves in Fig. 1 also demonstrate the significantly better
antiemetic outcome in the intervention group for the contin-
uous “CR emesis” vs. days at emetic risk (log-rank, p<
0.001). Over the whole period, 35.4% (17 of 48) of patients
in the control group had a CR compared to 76.0% (38 of 50)
in the intervention group (p<0.001). Thus, pharmaceutical
care led to an absolute risk reduction for experiencing emet-
ic episodes of 40.6%, which associates with a number
needed to treat of 3.
Severity of nausea and frequency of vomiting
In the intervention group, the median severity of acute
nausea was reduced by 39.4% compared to the control
group. Median severity of delayed nausea was reduced by
34.5%. However, the differences between groups were not
statistically significant. In contrast, there was a significant
reduction in the frequency of emetic episodes (Table 3).
Quality of life
The EORTC QLQ-C30 questionnaire is divided into global
health as superior measure as well as functioning and symp-
tom scales. Table 4 shows the absolute changes in quality of
life from baseline to end of chemotherapy, respectively, for
all scales. In particular, global health, social functioning, as
well as the symptom scales “nausea and vomiting,” and








Mean (SD) age (years) 54.4 (11.4) 49.6 (11.2) 0.047
Sex 0.742
Female 47 (97.9) 50 (100.0)
Male 1 (2.1) 0
Diagnosis 0.482
Breast cancer 43 (89.6) 47 (94.0)
Ovarian cancer 5 (10.4) 3 (6.0)
Chemotherapy regimen <0.001
EC 23 (47.9) 10 (20.0)
FEC 6 (12.5) 15 (30.0)
EC-T 0 9 (18.0)
EC-Doc 2 (4.2) 8 (16.0)
AC 3 (6.3) 0
FEC-Doc 0 2 (4.0)
PC 5 (10.4) 3 (6.0)
Not known 9 (18.8) 3 (6.0)
Marital status 0.401
Married/partner 36 (75.0) 43 (86.0)
Single 3 (6.3) 3 (6.0)
Divorced 4 (8.3) 4 (8.0)
Widow 4 (8.3) 0
No answer 1 (2.1) 0
Self-aid group 0.347
Yes 3 (6.3) 1 (2.0)
No 44 (91.7) 49 (98.0)
No answer 1 (2.1) 0
EC epirubicin, cyclophosphamide; FEC fluorouracil, epirubicin, cy-
clophosphamide; EC-T epirubicin, cyclophosphamide, paclitaxel; EC-
Doc epirubicin, cyclophosphamide, docetaxel; AC doxorubicin, cyclo-
phosphamide; FEC-Doc fluorouracil, epirubicin, cyclophosphamide,
docetaxel; PC paclitaxel, carboplatin
Table 2 Number of patients with or without “CR emesis” (in percent)
Control group Intervention group p value
n CR No CR n CR No CR
Cycle 1 47 23 (48.9) 24 (51.1) 48 44 (91.7) 4 (8.3) <0.001
Cycle 2 46 29 (63.0) 17 (37.0) 49 43 (87.8) 6 (12.2) 0.008
Cycle 3 44 27 (61.4) 17 (38.6) 48 45 (93.8) 3 (6.2) <0.001
Cycle 4 40 24 (60.0) 16 (40.0) 48 46 (95.8) 2 (4.2) <0.001
Cycle 5 14 11 (78.6) 3 (21.4) 27 26 (96.3) 1 (3.7) 0.107
Cycle 6 12 9 (75.0) 3 (25.0) 26 24 (92.3) 2 (7.7) 0.301
Fig. 1 Kaplan–Meier estimates of continuous “CR emesis” (only days
of emetic risk are shown, which were defined as the first 5 days of a
cycle)
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“appetite loss” were positively affected by pharmaceutical
care. When the absolute change was calculated only from
baseline to the middle of chemotherapy the scale “pain” was
also significantly affected (see Online resource 1). The
longitudinal evaluation over time showed significant
differences for the symptom scales “pain” (p00.023)
and “appetite loss” (p00.009).
Patient satisfaction with information
The PS-CaTE questionnaire can be divided into four sub-
scales (satisfaction with information on cancer treatment,
side effects, complementary treatment options, and satisfac-
tion with information sources) and global satisfaction as
superior measure. Patient satisfaction with information was
significantly improved upon pharmaceutical care (Table 5).
The median values on a five-point Likert scale (10very
dissatisfied to 50very satisfied) could be improved by
10% for cancer treatment, 7.5% for side effects, 5% for
complementary treatment options, 12.5% for information
sources, and 12.8% for global satisfaction (all calculated
as relative changes), respectively. Except for the com-
plementary treatment options scale, all improvements
were statistically significant (Table 5).
Influence of aprepitant
During the course of the study, aprepitant was introduced for
the prevention and treatment of nausea and vomiting and
was integrated into the standard guidelines. Due to the
sequential design, a higher proportion of patients of the
intervention group were treated with aprepitant compared
to the control group (35 of 50 vs. 5 of 47 patients). In order
to discriminate between the influence of aprepitant and
pharmaceutical care, a logistic regression analysis was per-
formed using the inclusion method.
The model revealed a statistically significant influence of
pharmaceutical care on CR emesis, whereas treatment with
aprepitant showed no significant influence (p00.003 vs. p0
0.670). The odds ratio for the influence of pharmaceutical
care was 5.4 (95% CI, 1.8–16.5) compared to 1.2 (95% CI,
0.5–3.3) for treatment with aprepitant. Thus, patients have a
fivefold higher chance of showing a CR when changing
from control to intervention group, and treatment with apre-
pitant did not bias the results to a significant extent.
Table 3 Severity of nausea and frequency of vomiting
Control group Intervention group p value
n Median Quartiles n Median Quartiles
Nausea
Acute 47 3.3 0.3; 10.3 47 2.0 0.0; 5.0 0.131
Delayed 48 11.9 0.8; 27.2 49 7.8 0.4; 19.7 0.324
Vomiting
Acute 47 0.3 0.0; 1.5 49 0.0 0.0; 0.0 <0.001
Delayed 48 0.1 0.0; 0.5 49 0.0 0.0; 0.0 0.002
Table 4 Absolute change of
quality of life from baseline to
the end of chemotherapy
Control group Intervention group p value
n Median Quartiles n Median Quartiles
Global health 37 −8.3 −29.2; 0 49 0 −16.7; 12.5 0.020
Functioning scales
Physical functioning 36 −6.7 −25.0; 5.0 46 0 −13.3; 8.3 0.145
Role functioning 34 0 −33.3; 16.7 49 0 −33.3; 16.7 0.496
Emotional functioning 34 −65.4 −81.7; −45.3 48 −64.3 −81.3; −47.3 0.799
Cognitive functioning 38 0 −16.7; 16.7 49 −16.7 −16.7; 0 0.169
Social functioning 39 0 −33.3; 16.7 49 0 −8.3; 16.7 0.058
Symptom scales
Fatigue 37 11.1 0; 55.6 49 22.2 0; 33.3 0.540
Nausea and vomiting 38 33.3 12.5; 50.0 49 16.7 0; 33.3 0.003
Pain 36 0 −16.7; 16.7 47 0 −33.3; 16.7 0.276
Dyspnea 36 16.7 0; 33.3 49 0 0; 33.3 0.940
Insomnia 37 0 0; 33.3 49 0 −16.7; 33.3 0.368
Appetite loss 39 33.3 0; 66.7 49 0 −16.7; 33.3 0.010
Constipation 38 33.3 0; 66.7 49 0 0; 33.3 0.100
Diarrhea 38 0 0; 0 49 0 0; 0 0.763
Financial difficulties 38 0 0; 33.3 47 0 0; 0 0.254
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Discussion
Pharmaceutical care in oncology aims at reducing treatment-
associated toxicity and at improving patients’ quality of life.
During this project, a specific pharmaceutical care model for
breast and ovarian cancer patients was implemented, including
optimization of supportive medication and patient counseling
on the management of treatment-associated adverse effects.
The study revealed a benefit for the patients receiving pharma-
ceutical care based on improved PROs.
Strengths and limitations
The major strength of this study is that it was entirely
conducted under real-life conditions. A control group design
was selected as the most suitable and generally accepted
method. However, a number of limitations have to be con-
sidered before interpreting the data. Besides the relatively
small number of patients, a nonrandomized study design
was chosen. Since pharmaceutical care must be regarded
as a highly complex intervention, some limitations with
regard to the study design had to be accepted [18]. A parallel
design with randomization could have led to significant
contamination bias because of the interaction that occurs
between clinic patients. In oncologic practices and outpa-
tient clinics, patients have many possibilities of meeting
each other and talking about the procedures and quality of
care provided. It would have been impossible to avoid that
patients of the control group would have noticed that other
patients receive more information and attention than they
do. Since especially cancer patients increasingly demand
attention from health care professionals, a stringent refusal
of pharmaceutical care to some of the patients would have
been neither practical nor ethical. In addition, since blinding
is not possible with this intervention, health care professio-
nals might have adopted an approach to patient follow-up
counseling that was dependent upon the intervention re-
ceived. Therefore, we decided to recruit first the control
group and subsequently the intervention group in each
participating center.
Using a sequential enrolment instead of randomization
led to some differences between the control and the
intervention group that might potentially have influenced
the results. First of all, the control group had a median age of
54.4 years compared to 49.6 years in the intervention group.
Studies demonstrated that younger age is associated with a
higher risk of vomiting [19]. Thus, the significantly better
“CR emesis” in the intervention group was not positively
biased by this difference. The second major difference can
be found in the treatment regimens that have been used.
Since the patients were approached consecutively, the ob-
served difference in drugs and dosages is simply random
and partly caused by the prior recruitment of the control
group. Whereas the majority of the control group was trea-
ted with a combination of two drugs (54.2%), the majority
of the intervention group received a combination (30%) or
sequential treatment (34%) of three drugs. However, in both
groups, the chemotherapy regimens were all classified as
“moderately emetogenic” based on evidence-based guidelines
[20]. Therefore, the emetic risk can be regarded as comparable
in both groups.
Nausea and vomiting
The primary endpoint “CR emesis” was significantly im-
proved in the intervention group (35.4% of the control
group vs. 76.0% of the intervention group, p<0.001). This
improvement can be accounted to the different components
of the intervention. First of all, the intervention included the
suggestion of a standardized, evidence-based antiemetic
prophylaxis. Second, the intervention aimed at improving
patients’ knowledge and discernment in the therapy and thus
enhancing the concordance to the suggested prophylaxis.
Especially for patients receiving a moderately emetogenic
chemotherapy, antiemetic guidelines are often not applied
[21] and implementation of guidelines into daily clinical
practice is difficult [22].
The main difference of our algorithm to the previous
practice in the participating centers was the reinforcement
of a prophylactic antiemetic treatment and the evidence-
based prevention of delayed emesis. Prior to the pharma-
cists’ intervention, the antiemetic treatment for the delayed
phase was prescribed on demand. In addition, corticoste-
roids were rarely used and there was a widespread use of
Table 5 Patient satisfaction
with cancer treatment education Control group Intervention group p value
n Median Quartiles n Median Quartiles
Cancer treatment 41 4.0 3.7; 4.2 49 4.4 4.0; 4.8 0.017
Side effects 41 4.0 3.1; 4.3 49 4.3 4.0; 5.0 0.002
Complementary treatment options 41 4.0 3.0; 4.3 46 4.2 3.0; 5.0 0.145
Information sources 41 4.0 3.8; 4.8 49 4.5 4.0; 5.0 0.005
Global satisfaction 41 3.9 3.5; 4.2 49 4.4 3.8; 4.8 0.009
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5-HT3 antagonists for the prevention of delayed emesis.
However, since this study was an observational study, it
was not mandatory for treating physicians to follow the
proposed algorithm for antiemetic prophylaxis and some
deviations were still observed. Some physicians were reluc-
tant to prescribe oral dexamethasone treatment on days 2
and 3 of the first cycle and only added dexamethasone in
subsequent cycles of chemotherapy if the patient had major
problems with nausea and vomiting. 5-HT3 antagonists were
further used instead, even though this treatment has only
limited efficacy in the prevention of delayed emesis. One
could speculate that the consequent adherence to the guide-
lines would have resulted in even higher rates of CR in the
intervention group and a more cost-effective treatment as
dexamethasone is substantially less costly than 5-HT3 antag-
onists [23]. Nevertheless, even though physicians deviated
from the agreed antiemetic algorithm in some patients of the
intervention group, the majority received a guideline-
conforming prophylaxis which can be regarded as improve-
ment compared to the control group.
One major difference between the control group and the
intervention group was the use of the NK1 receptor
antagonist aprepitant. This drug was introduced during the
course of the study and was rapidly implemented into inter-
national treatment guidelines for chemotherapy-induced
nausea and vomiting [20]. Due to the later recruitment, a
significantly larger proportion of patients of the intervention
group was treated with aprepitant compared to the control
group (35 vs. 5 patients). Therefore, we wanted to explore
whether the intervention itself and not the use of aprepitant
was responsible for the observed difference between the
intervention group and the control group. The logistic regres-
sion performed showed that treatment with aprepitant as
influencing factor alone did not result in statistically signif-
icant differences between the control group and the interven-
tion group, whereas pharmaceutical care had a significant
influence and resulted in an about fivefold increase of “CR
emesis.” Comparing the results of the intervention group with
the results of a study evaluating the efficacy of aprepitant in
breast cancer patients receiving moderately emetogenic che-
motherapy, the latter patient group showed a “CR emesis” of
51% [24] compared to 76% in our study. This supports the
conclusions from the logistic regression that the improvement
of the intervention group is also a result of pharmaceutical
care and not only the use of aprepitant. However, the question
remains whether pharmaceutical care is still effective when
NK1 antagonists are widely used. In a recent study in two
German university hospitals, a structured nursing intervention
did not result in a significant reduction of nausea and emesis.
The authors conclude that the impact of information and
counseling programs on acute and delayed nausea and emesis
might be limited when antiemetics are properly used [25].
Future studies will have to clarify this aspect.
In contrast to vomiting, patients of the intervention group
did not show significant improvement regarding the severity
of nausea both in the acute and delayed phases. A trend
towards better outcomes in the intervention group could be
observed; however, this did not reach statistical significance.
Quality of life
Health-related quality of life includes physical, psychologi-
cal, social, and functional dimensions [26]. The results for
quality of life showed that global health as a determinant of
overall quality of life was significantly improved in the
intervention group. Furthermore, symptom scales such as
“appetite loss” and “nausea and vomiting” showed signifi-
cantly better results in the intervention group. These symp-
toms are closely linked to the antiemetic outcome.
Improvement in these symptom scales are an indicator for
a better overall quality of life [27]. Quality of life as a
multidimensional construct is subject to large variability
and various influencing factors. Different personalities
(e.g., optimistic or pessimistic) as well as coping strategies
affect quality of life substantially [28–31]. Therefore, with
the limited patient number in our study, it was difficult to
observe statistically significant differences.
Patient satisfaction with information
Significant improvements in the intervention group were
measured for the global scale and all subscales of the
PS-CaTE questionnaire, except for information regarding
complementary treatment options. These results demon-
strate that the pharmaceutical care model may help
increase the knowledge of the patients on different
aspects of their treatment such as side effects. In con-
trast, patients were not actively informed on options for
complementary treatments as evidence-based recommen-
dations are lacking, which might explain the nonsignif-
icant results for this scale. In general, information needs
of cancer patients change with the course of their treat-
ment [32]. For example, patients who were just recently
diagnosed look for information on efficacy of treatment,
potential side effects, supportive strategies, and conse-
quences for their family life [33]. The advantage of our
pharmaceutical care model is that it follows a needs-
based approach with regard to patient information.
Further considerations
When interpreting the data, one has to keep in mind that
social effects may have influenced the data. It can be ob-
served that patients who participate in studies regardless of
the treatment and whether they are assigned to the control or
intervention group seem to benefit. The manner in which
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patients are cared for in terms of emotional and cogni-
tive care can influence the treatment outcome [34]. It
might be interesting to investigate the relevance of such
“context effects” on the outcome of pharmaceutical care
in appropriate studies.
Outlook
This study was conducted to explore the feasibility and the
potential of a pharmaceutical care model by measuring
PROs. With the study design selected, it was, however, not
possible to fully evaluate the effectiveness of pharmaceuti-
cal care for cancer patients. Nevertheless, our study showed
that pharmaceutical care models may help improve the
quality of cancer care and are worth being investigated in
larger trials involving a higher number of participating cen-
ters. In this case, patients in different oncologic outpatient
clinics or practices could be randomly allocated to a partic-
ular intervention. Such “cluster randomized trials” are one
solution to the problem of contamination of the control
group and are increasingly used to evaluate complex inter-
ventions in health care [18, 35]. Moreover, the cost–benefit
ratio of pharmaceutical care should be assessed in future
studies in order to enforce the implementation of this
intervention in clinical routine. Further studies and ad-
vanced activities in this area will certainly strengthen
multidisciplinary and intersector collaboration in daily
routine, which is urgently warranted to enhance patient
safety in cancer therapy.
Conclusions
In conclusion, our results suggest that pharmaceutical care for
patients with breast and ovarian cancer is feasible and may
have an impact on PROs as particularly indicated by signifi-
cant improvements of the antiemetic response and patient
satisfaction. Although there is no doubt that a higher aware-
ness of drug-related problems is beneficial, final conclusions
on the effectiveness of a new health care intervention can only
be drawn when studied in a randomized trial. Therefore,
our data may serve as a valuable basis for planning a
large randomized multicenter trial.
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